Clinical Trial Update: Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS) [Phase 2]

View source ↗

Summary

This Phase 2 study (MRD-ATLAS) is evaluating whether circulating tumor DNA–based minimal residual disease guidance can inform adjuvant therapy after neoadjuvant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING